HCV Vaccine

Structure of HCV
enveloped group virus
Positive sense , ssRNA
Is a vaccine necessary ?
Yes ,
Marked reduction in HCV incidence
limitation of current therapy :
- Reinfection.
- Cost.
- Side effect.

Conclusion
Clinical trials are ongoing and treatment will be soon available. day by day, hope becomes actually more tangible
OverView
Structure of HCV .
Is a vaccine necessary ?
Why there is no vaccine yet ?
The role of Humoral and Cell-Mediated Immune Responses
Trials for an effective vaccine .
codes for structural proteins (core,E1,E2)
codes for non-structural proteins (NS1:NS5B)
Why there is no vaccine yet ?
Genomic variability of HCV.
Escaping from neutralization:
The shielding of neutralizing epitopes by glycosylation of defined amino acids of envelope glycoprotein.
The association of HCV with serum factors such as LDL and very low-density lipoprotein (VLDL).
Adenoviral based vaccine of HCV
http://stm.sciencemag.org/content/4/115/115ra1

Elicit HCV-specific T cells .

Two adenoviral vectors expressing NS and core proteins from HCV genotype 1b were constructed based on rare serotypes

T cell responses targeted multiple proteins and were capable of recognizing heterologous strains and could be sustained for at least a year after boosting with the heterologous adenoviral vector.

The hepatitis C first ‘prime’ vaccine is based on a chimpanzee adenovirus called ChAd3.

The second ‘boost’ vaccine – a modified vaccine Ankara (MVA) virus.

Neither the adenovirus nor MVA is able to replicate, so they packaged up inside can’t cause a hepatitis C infection either.



http://www.ox.ac.uk/news/2014-11-05-new-vaccine-generates-strong-immune-response-against-hepatitis-c-0.

Woodland, D. L. (2004). Jump-starting the immune system: prime–boosting comes of age. Trends in immunology, 25(2), 98-104.‏
INO-8000 / VGX-6150 Vaccine
http://www.inovio.com/products/infectious-disease-vaccines/hepatitis/ino8000HCV/

Inovio Pharmaceuticals.

Phase 1 synthetic multi-antigen DNA immunotherapy.

Inovio's SynCon design is intended to provide broader protection against new mutations of a virus.

Covering hepatitis C virus (HCV) genotypes 1a and 1b.



Consists of three plasmid DNAs and an adjuvant plasmid expressing IL-28B.

Target NS3, NS4A, NS4B and NS5A.

The vaccine is delivered via the Cellectra® electroporation delivery device.

Tested in chronically infected patients who have previously failed standard drug therapy.


http://en.wikipedia.org/wiki/Hepatitis_C
The role of Humoral and Cell-Mediated Immune Responses

Prepared by :

Mohamed Nosser , Sara Hamouda,

Hossam

Gadallah



Faculty of Pharmacy
Tanta University

Under supervision of :

Dr/ Fotouh Rashed Mansour


A new promising vaccine
for HCV